Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals ($INO), AstraZeneca's ($AZN) MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds. The Defense Advanced Research Projects Agency (DARPA) is paying for the project, through which the group will develop DNA-based antibodies for infectious diseases, focusing on the flu, Pseudomonas aeruginosa and Staphylococcus aureus. More

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.